Innate Pharma S.A. (IPHA) Financials
IPHA Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 39.6 million | 85.8 million |
| March 31, 2026 | 71.8 million | 96.7 million |
| Dec. 31, 2025 | 73.6 million | 99.1 million |
| June 30, 2025 | 109.5 million | 103.5 million |
IPHA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -24.4 million | ? |
| March 31, 2026 | -26.9 million | ? |
| Dec. 31, 2025 | -27.6 million | ? |
| June 30, 2025 | -40.2 million | 1.8 million |
IPHA Net Income
No data available :(
IPHA Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 12.4 million | 10.7 million | 50194 |
| March 31, 2026 | 39.3 million | - | - |
| Dec. 31, 2025 | 40.3 million | 16.1 million | 450802 |
| June 30, 2025 | 70.8 million | 21.1 million | 736663 |
IPHA Shares Outstanding
IPHA Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 104098 | - | 8.5 million | - |
| March 31, 2026 | 97466 | 26.3 million | 1.6 million | - |
| Dec. 31, 2025 | 99847 | 26.9 million | 1.4 million | -183138 |
| June 30, 2025 | 74665 | 24.2 million | 11.5 million | 183871 |
IPHA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 3.6 million | - |
| March 31, 2026 | -2.4 million | - |
| Dec. 31, 2025 | -2.4 million | - |
| June 30, 2025 | 5.7 million | 24.2 million |
IPHA
Price: $1.43
52 week price:
Earnings Per Share: -0.59 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: France
Volume: 6529
Market Capitalization: 149.3 million